Samenvatting MA301
,Inhoud
Hoorcolleges...........................................................................................................................5
HC Supportive Care .............................................................................................................5
Bijwerkingen ....................................................................................................................5
Behandeling van overdoseringen ..................................................................................... 12
HC Klassieke oncologie ...................................................................................................... 13
Celcyclus specifieke middelen ....................................................................................... 14
Antimetabolieten ........................................................................................................... 16
Taxanen ......................................................................................................................... 17
Vinca-alkaloïden ............................................................................................................ 17
Topo-isomerase remmers ............................................................................................... 18
Alkylerende middelen ..................................................................................................... 18
Platinaverbindingen ........................................................................................................ 20
Cytotoxische antibiotica ................................................................................................. 21
Combinatiebehandelingen ............................................................................................. 21
HC therapeutische principes .............................................................................................. 22
Vaststellen dosis oncolytica ........................................................................................... 22
Ontwikkeling doelgerichte behandeling ........................................................................... 23
Interpatiënt variatie ........................................................................................................ 24
Oorzaken variatie ........................................................................................................... 25
Geneesmiddelinteracties ............................................................................................... 27
Genetische verschillen ................................................................................................... 27
Dosis optimaliseren ....................................................................................................... 28
HC Evidence voor besluitvorming ....................................................................................... 28
Besluitvorming ............................................................................................................... 28
Eindpunten .................................................................................................................... 29
Studiedesign .................................................................................................................. 32
Praktijk........................................................................................................................... 33
HC Health Technology Assessment .................................................................................... 34
HC Moderne Oncologie I .................................................................................................... 38
Leukemie – CML ............................................................................................................. 39
Longkanker .................................................................................................................... 41
Melanoom...................................................................................................................... 42
Borstkanker.................................................................................................................... 43
HC Moderne Oncologie II ................................................................................................... 45
Immunotherapie bij melanoom en IL-2 als immunotherapie............................................. 45
, Immunotherapie bij andere tumoren ............................................................................... 47
Adoptieve immunotherapie............................................................................................. 49
Nieuwe therapieën ......................................................................................................... 50
HC Palliatieve zorg en pijn .................................................................................................. 51
Palliatieve zorg ............................................................................................................... 51
Pijnbehandelingen.......................................................................................................... 53
Neuropatische pijn ......................................................................................................... 58
HC Levenseindevraagstukken en euthanasie (incl. longitudinale patiënt week 5) .................. 59
Deel 1 ............................................................................................................................ 59
Deel 2 ............................................................................................................................ 60
Longitudinale patiënt week 5 .......................................................................................... 62
HC Hormoontherapie......................................................................................................... 63
LHRH-a(nta)gonisten ...................................................................................................... 63
Androgeenblokkers ........................................................................................................ 64
Oestrogenen .................................................................................................................. 64
Borstkanker.................................................................................................................... 65
CBL’s .................................................................................................................................... 65
CBL1 ................................................................................................................................. 65
CBL2 ................................................................................................................................. 74
CBL3 ................................................................................................................................. 82
CBL4 ................................................................................................................................. 91
Longitudinale patiënt ............................................................................................................. 99
Week 1 deel 1 .................................................................................................................... 99
Week 1 deel 2 .................................................................................................................. 100
Week 2 deel 1 .................................................................................................................. 100
Week 2 deel 2 .................................................................................................................. 102
Week 3 ............................................................................................................................ 103
Week 4 deel 1 .................................................................................................................. 104
Week 4 deel 2 .................................................................................................................. 105
Leerboek oncologie hoofdstuk 9 .......................................................................................... 105
Resistentie ................................................................................................................... 105
Resistentie - Klinische resistentie.................................................................................. 106
Indeling en werkingsmechanismen ................................................................................... 107
Alkylerende middelen ................................................................................................... 107
Platinaverbindingen ...................................................................................................... 107
Topo-isomeraseremmers .............................................................................................. 108
, Microtubulaire remmers ............................................................................................... 108
Antimetabolieten ......................................................................................................... 108
Hormoonbehandeling .................................................................................................. 109
Moleculair doelgerichte behandelingen ............................................................................ 109
Specifieke medicatie – antilichamen ............................................................................. 110
Specifieke medicatie – kinaseremmers ......................................................................... 110
Tabel -mabs en kleine moleculen .................................................................................. 111
Immunotherapie .......................................................................................................... 112
Klinische toepassing..................................................................................................... 112
,Inhoud
Hoorcolleges...........................................................................................................................5
HC Supportive Care .............................................................................................................5
Bijwerkingen ....................................................................................................................5
Behandeling van overdoseringen ..................................................................................... 12
HC Klassieke oncologie ...................................................................................................... 13
Celcyclus specifieke middelen ....................................................................................... 14
Antimetabolieten ........................................................................................................... 16
Taxanen ......................................................................................................................... 17
Vinca-alkaloïden ............................................................................................................ 17
Topo-isomerase remmers ............................................................................................... 18
Alkylerende middelen ..................................................................................................... 18
Platinaverbindingen ........................................................................................................ 20
Cytotoxische antibiotica ................................................................................................. 21
Combinatiebehandelingen ............................................................................................. 21
HC therapeutische principes .............................................................................................. 22
Vaststellen dosis oncolytica ........................................................................................... 22
Ontwikkeling doelgerichte behandeling ........................................................................... 23
Interpatiënt variatie ........................................................................................................ 24
Oorzaken variatie ........................................................................................................... 25
Geneesmiddelinteracties ............................................................................................... 27
Genetische verschillen ................................................................................................... 27
Dosis optimaliseren ....................................................................................................... 28
HC Evidence voor besluitvorming ....................................................................................... 28
Besluitvorming ............................................................................................................... 28
Eindpunten .................................................................................................................... 29
Studiedesign .................................................................................................................. 32
Praktijk........................................................................................................................... 33
HC Health Technology Assessment .................................................................................... 34
HC Moderne Oncologie I .................................................................................................... 38
Leukemie – CML ............................................................................................................. 39
Longkanker .................................................................................................................... 41
Melanoom...................................................................................................................... 42
Borstkanker.................................................................................................................... 43
HC Moderne Oncologie II ................................................................................................... 45
Immunotherapie bij melanoom en IL-2 als immunotherapie............................................. 45
, Immunotherapie bij andere tumoren ............................................................................... 47
Adoptieve immunotherapie............................................................................................. 49
Nieuwe therapieën ......................................................................................................... 50
HC Palliatieve zorg en pijn .................................................................................................. 51
Palliatieve zorg ............................................................................................................... 51
Pijnbehandelingen.......................................................................................................... 53
Neuropatische pijn ......................................................................................................... 58
HC Levenseindevraagstukken en euthanasie (incl. longitudinale patiënt week 5) .................. 59
Deel 1 ............................................................................................................................ 59
Deel 2 ............................................................................................................................ 60
Longitudinale patiënt week 5 .......................................................................................... 62
HC Hormoontherapie......................................................................................................... 63
LHRH-a(nta)gonisten ...................................................................................................... 63
Androgeenblokkers ........................................................................................................ 64
Oestrogenen .................................................................................................................. 64
Borstkanker.................................................................................................................... 65
CBL’s .................................................................................................................................... 65
CBL1 ................................................................................................................................. 65
CBL2 ................................................................................................................................. 74
CBL3 ................................................................................................................................. 82
CBL4 ................................................................................................................................. 91
Longitudinale patiënt ............................................................................................................. 99
Week 1 deel 1 .................................................................................................................... 99
Week 1 deel 2 .................................................................................................................. 100
Week 2 deel 1 .................................................................................................................. 100
Week 2 deel 2 .................................................................................................................. 102
Week 3 ............................................................................................................................ 103
Week 4 deel 1 .................................................................................................................. 104
Week 4 deel 2 .................................................................................................................. 105
Leerboek oncologie hoofdstuk 9 .......................................................................................... 105
Resistentie ................................................................................................................... 105
Resistentie - Klinische resistentie.................................................................................. 106
Indeling en werkingsmechanismen ................................................................................... 107
Alkylerende middelen ................................................................................................... 107
Platinaverbindingen ...................................................................................................... 107
Topo-isomeraseremmers .............................................................................................. 108
, Microtubulaire remmers ............................................................................................... 108
Antimetabolieten ......................................................................................................... 108
Hormoonbehandeling .................................................................................................. 109
Moleculair doelgerichte behandelingen ............................................................................ 109
Specifieke medicatie – antilichamen ............................................................................. 110
Specifieke medicatie – kinaseremmers ......................................................................... 110
Tabel -mabs en kleine moleculen .................................................................................. 111
Immunotherapie .......................................................................................................... 112
Klinische toepassing..................................................................................................... 112
